obesity drug news today glp-1 october 2025 Alarming rise in weight loss overdoses Rhode Island considers ending Medicaid
Description
PlexusDx compounded medications remain HSA/FSA eligible regardless of genetic testing results, ensuring financial barriers never prevent access to precision therapy
Understanding whether combination therapy or monotherapy suits your individual biology requires more than clinical guidelines alone
Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice
The market for glucagon-like peptide-1 (GLP-1) agonists has seen tremendous development and transition, driven by a variety of factors that affect its direction
